Cancer Clinical Trials

The UCI Health Chao Family Comprehensive Cancer Center is now enrolling patients in these featured clinical trials.

To refer a patient or get more information about a clinical trial, click on the principal investigator’s name to send an email. You may also contact us at ucsstudy@uci.edu or 877-UC-Study. To search all cancer clinical trials now available at UCI Health, visit cancer.uci.edu/clinical-trials-flowcharts

Brain and nervous system

EF-32: A pivotal, randomized, open-label study of Optune® (tumor treating fields, 200Hz) concomitant with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma (UCI 20-65/EF-32 TRIDENT)
For more information, contact principal investigator Scott G. Turner, MD

A phase 1b trial of telaglenastat (CB-839) HCI in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (ETCTN-10218)
For more information, contact principal investigator Xiao-Tang Kong, MD

Breast

A CompassHER2 residual disease (RD), double-blinded, phase 3 randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib (A011801)
For more information, contact principal investigator Ritesh Parajuli, MD
A randomized phase 1/2 trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) vs. fulvestrant and abemaciclib alone (FA) for endocrine-resistant, hormone-receptor positive, HER2-negative metastatic breast cancer (FAC vs FA) (ETCTN-10287)

*For more information, contact principal investigator Ritesh Parajuli, MD*

**Gastrointestinal**

A randomized phase 3 study of immune checkpoint inhibition with chemotherapy in treatment-naïve metastatic anal cancer patients (EA2176)

*For more information, contact principal investigator May Cho, MD*

A phase 2 trial of sequential systemic therapy plus intraperitoneal paclitaxel in gastric/gastroesophageal junction cancer peritoneal carcinomatosis (UCI 20-87)

*For more information, contact principal investigator Maheswari Senthil, MD*

**Genitourinary**

A phase 2 study of olaparib (AZD2281) in patients with metastatic/advanced urothelial carcinoma with DNA-repair defects (ETCTN-10144)

*For more information, contact principal investigator Arash Rezazadeh Kalebasty, MD*

A phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG) (UCI 20-91/CG2003C)

*For more information, contact principal investigator Edward Uchio, MD*

A phase 3, open-label, randomized, controlled study of enfortumab vedotin in combination with pembrolizumab vs. chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer (UCI 19-143/EV-302)

*For more information, contact principal investigator Nataliya Mar, MD*

**Gynecologic oncology**

A phase 1b/2, first-in-human, dose-escalation and dose-expansion study of XMT-1536 in patients with solid tumors likely to express NaPi2b (GOG-3048)

*For more information, contact principal investigator Jill Tseng, MD*

A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-56-500 in combination with paclitaxel in patients with platinum-resistant recurrent
ovarian cancer (GOG-3059)

For more information, contact principal investigator Fabio Cappuccini, MD

Head and neck

Randomized phase 2 and phase 3 studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) (HN001)

For more information, contact principal investigator Rupali Nabar, MD

A randomized phase 2/3 trial of adjuvant radiation therapy with cisplatin and docetaxel-cetuximab or cisplatin-atezolizumab in pathologic, high-risk squamous cell cancer of the head and neck (RTOG-1216)

For more information, contact principal investigator Rupali Nabar, MD

Hematologic malignancies

A phase 3, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of tafasitamab plus lenalidomide in addition to rituximab vs. lenalidomide in addition to rituximab in patients with relapsed/refractory follicular lymphoma grade 1-3a or relapsed/refractory marginal zone lymphoma (UCI 20-148)

For more information, contact principal investigator Elizabeth Brém, MD

A phase 4, multicenter, open-label feasibility study to evaluate outpatient blinatumomab administration in adult subjects with minimal residual disease of B-precursor acute lymphoblastic leukemia in complete hematologic remission (UCI 20-34)

For more information, contact principal investigator Deepa Jeyakumar, MD

Hepatobiliary

A phase 1/2 study of M3814 (pemperitib) in combination with hypofractionated radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma (ETCTN-10366)

For more information, contact principal investigator Farshid Dayyani, MD

A phase 1b/2, open-label, multicenter, randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with advanced liver cancers (Morpheus-Liver) (UCI 20-79)

For more information, contact principal investigator Farshid Dayyani, MD
Lung

A phase 1b/2, open-label, multicenter study of ERAS-007 in combination with other anti-cancer therapies in patients with advanced non-small-cell lung cancer (HERKULES-2) (UCI 21-63)

For more information, contact principal investigator Sai-Hong Ou, MD

A phase 1a/1b, dose-escalation and dose-expansion study evaluating the safety, pharmacokinetics and activity of GDC-6036 as a single agent and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumors with a KRAS G12C mutation (UCI 20-141/GO42144)

For more information, contact principal investigator Sai-Hong Ou, MD

Skin

A phase 1/2 study of dabrafenib, trametinib and navitoclax in BRAF-mutant melanoma (phase 1 and 2) and other solid tumors (phase 1 only) (ETCTN-9466)

For more information, contact principal investigator Justin Moyers, MD

A phase 2 study to investigate the efficacy and safety of lerapoltrev (PVSRIPO) with and without immune checkpoint blockade in advanced PD-1 refractory melanoma (UCI 20-174/LUMINOS-102)

For more information, contact principal investigator Justin Moyers, MD